Received Dec 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 34N52 | — |
Flulaval Second dose given before minimum interval; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 2-year-old male patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) (batch number 34N52, expiry date 30-JUN-2026) for prophylaxis. Concomitant products included INFLUENZA VACCINE INACT SPLIT 3V (FLULAVAL). On 12-DEC-2025, the patient received the 2nd dose of FluLaval 2024-2025 season. On 12-DEC-2025, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced drug dose administration interval too short (Verbatim: Flulaval Second dose given before minimum interval). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 12-DEC-2025 A nurse had mentioned that a patient had initiated the primary Flu vaccination with a dose of Flulaval given on 24-NOV-2025. The patient had received the second dose today (on the day of reporting), which was administered one week before the minimum interval indicated in the PI (package insert). The HCP had asked for recommendations regarding this situation. The batch number was not provided upon follow- up with the reporter.